IDO1 and neoplasm: While current efforts are proceeding to account for the failure of selective IDO1 inhibitors to inhibit tumor growth, modulating other components of the kynurenine pathway or interacting systems could provide new avenues for identifying means of disrupting the inflammation–cancer link.